Astellas and AstraZeneca have announced the approval of Symbicort Turbuhaler for COPD. The budesonide/formoterol fumarate DPI has been available for the treatment of asthma in Japan since January 2010.
The two companies entered an agreement to co-promote Symbicort Turbuhaler in Japan in August 2009.
According to the companies, “The approval of Symbicort Turbuhaler for COPD alongside the existing adult bronchial asthma indication will allow Astellas and AstraZeneca to maximize the value of the product and further promote its appropriate use so as to improve the treatment of COPD in Japan.”
Read the Astellas and AstraZeneca press release.
